Clinical Trials Insight: 700016990
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Feb 2008
At a glance
- Drugs Monoclonal antibody 1D09C3 (Primary)
- Indications Lymphoproliferative disorders
- Focus Adverse reactions
- Sponsors Agennix AG
- 25 Feb 2008 GPC Biotech has discontinued internal development of 1D09C3.
- 27 Oct 2006 New trial record.